New inhaled drug aimed at stubborn lung infection shows promise, but trial halted early
Disease control
Terminated
This phase 3 study tested an inhaled form of the antibiotic clofazimine added to standard therapy for people with MAC lung disease that did not respond to previous treatment. The goal was to see if the drug could clear the infection from sputum cultures and improve quality of lif…
Phase: PHASE3 • Sponsor: Mannkind Corporation • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC